重组人血管内皮抑制素联合TP方案治疗晚期非小细胞肺癌临床观察.docVIP

重组人血管内皮抑制素联合TP方案治疗晚期非小细胞肺癌临床观察 　　1 (1.湖北省黄冈市中心医院,湖北黄冈438000;2.湖北省黄冈市黄州区人民医院,湖北黄冈438000; 　　3.湖北省黄冈市中医院,湖北黄冈438000) 　　 　　[摘要] 目的 观察YH-16联合紫杉醇和顺铂(TP)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和安全性,同时探讨循环血管内皮细胞(CECs)与该方案疗效的相关性。方法 比较观察组和对照组治疗晚期NSCLC的近期疗效及毒副反应,采用流式细胞学法检测治疗前后外周血CECs数量。结果 观察组和对照组有效率(CR+PR)分别为62.50%和22.22%(P=0.035);临床受益率分别为87.50%和50.00%(P=0.030);两组Ⅲ～Ⅳ级白细胞减少发生率分别为31.25%和33.33%;Ⅲ～Ⅳ级血小板减少发生率分别为25.00%和27.78%;恶心、呕吐发生率分别为56.24%和50.00%,差异无统计学意义(P0.05)。结论 YH-16联合TP疗效优于单独应用TP,不增加毒副反应,CECs可能是一个较好的预测化疗联合抗血管生成治疗疗效的标志。 　　[关键词] 非小细胞肺癌; 重组人血管内皮抑制剂; 联合化疗; 血管/细胞学 　　[中图分类号] R734.2 [文献标识码] A [文章编号] 1673-9701(2010)13-33-03 　　 　　Recombinant Human Endostatin Combined with Taxol Plus CisplatinRegimen in Treatment of Advanced Non-small Cell Lung Cancer:Clinical Observation 　　LIU Jing1 WANG Ping1 LUO Honglan1 WANG Changfeng1 CHEN Chuanxi1 SUN Yuanli1 YANG Lin1 ZANG Li1 JIAO Kewen1 GUI Ruifeng1 TAO Zhaohui2 YANG Li3 　　1.Huanggang City Central Hospital,Huanggang 438000,China;2.Huanggang City People’s Hospital,Huanggang 438000,China;3.Huanggang City Hospital of Traditional Chinese Medicine,Huanggang 438000,China 　　 　　[Abstract] ObjectiveTo investigate the short-term curative effect and safety of YH-16 in combination with Taxol plus cisplatin(TP)regimen in the treatment of advanced non-small cell lung cancer(NSCLC). MethodsThe recent efficacy and toxicity in the treatment of advanced NSCLC were compared between the experimental group and control group and the number of peripheral blood CECs before and after treatment was detected by flow cytometry. ResultsThe effective rates(CR+PR) of the experimental group and control group were 62.50% and 22.22%(P=0.035),and the clinical benefit response(CBR) of two groups was 87.5% and 50%,respectively(P=0.030). There was no significant difference in Ⅲ~ Ⅳ grade neutropenia incidence rate,Ⅲ~Ⅳ grade thrombocytopenia and nausea and vomiting incidence rate between two groups. ConclusionYH-16 combined with TP regimen is better than TP regimen alone in the treatme